Press Releases 2024 2023 2022 2021 2020 2019 all January 11, 2024 Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares January 5, 2024 Dyne Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference January 4, 2024 Dyne Therapeutics Announces Pricing of $300 Million Public Offering of Common Stock January 3, 2024 Dyne Therapeutics Announces Proposed Public Offering of Common Stock January 3, 2024 Dyne Therapeutics Announces Positive Initial Clinical Data from ACHIEVE Trial in DM1 Patients and DELIVER Trial in DMD Patients Demonstrating Promise of the FORCE™ Platform in Developing Therapeutics for Rare Muscle Diseases January 2, 2024 Dyne Therapeutics to Host Virtual Event Tomorrow, January 3 at 8:00 AM ET, to Present Initial Clinical Data from ACHIEVE and DELIVER Trials November 7, 2023 Dyne Therapeutics to Present at November Investor Conferences October 30, 2023 Dyne Therapeutics Reports Third Quarter 2023 Financial Results and Provides Update on Significant Progress for ACHIEVE and DELIVER Trials and Upcoming Clinical Milestones September 28, 2023 Dyne Therapeutics to Present at October Investor Conferences September 20, 2023 Dyne Therapeutics Receives FDA Orphan Drug Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 September 5, 2023 Dyne Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference August 3, 2023 Dyne Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights June 1, 2023 Dyne Therapeutics to Present at Jefferies Healthcare Conference May 25, 2023 Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101 May 17, 2023 Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting May 11, 2023 Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights May 3, 2023 Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference May 2, 2023 Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS March 23, 2023 Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy March 20, 2023 Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference Pagination First page « Previous page ‹ Page 1 Current page 2 Page 3 Page 4 Page 5 Page 6 Next page › Last page » Displaying 21 - 40 of 106
